4.8 Article

Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS

Journal

JOURNAL OF HEPATOLOGY
Volume 54, Issue 5, Pages 901-907

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2010.08.025

Keywords

Cirrhosis; Portal hypertension; TIPS; Refractory ascites; Survival model

Ask authors/readers for more resources

Background & Aims: Refractory ascites in patients with cirrhosis is associated with poor survival. TIPS is more effective than paracentesis for the prevention of recurrence of ascites but increases the risk of encephalopathy while survival remains unchanged. A more accurate selection of the patients might improve these results. The aim of the present study was to identify parameters of prognostic value for survival in patients with refractory ascites treated with TIPS. Methods: One hundred and five consecutive French patients with cirrhosis and refractory ascites treated with TIPS were used to assess parameters associated with 1-year survival. The model was then tested in two different cohorts: a local and prospective one including 40 patients from Toulouse, France, and an external one including 48 patients from Barcelona, Spain. Results: The actuarial rate of survival in the first 105 patients was 60% at 1 year. Using multivariate analysis, only lower bilirubin levels and higher platelet counts were independently associated with survival. The actuarial 1-year survival rate in patients with both a platelet count above 75 x 10(9)/L and a bilirubin level lower than 50 mu mol/L [3 mg/dl] was 73.1% as compared to 31.2%, in patients with a platelet count below 75 x 10(9)/L or a bilirubin level higher than 50 mu mol/L. These results were confirmed in the two different validation cohorts. Conclusions: The combination of a bilirubin level below 50 mu mol/L and a platelet count above 75 x 10(9)/L is predictive of survival in patients with refractory ascites treated with TIPS. This simple score could be used at bedside to help choose the best therapeutic options. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available